caa a22 4500 475824695 CHVBK 20180406123828.0 cr unu---uuuuu 170329e20001001xx s 000 0 eng 10.1023/A:1018782708070 doi (NATIONALLICENCE)springer-10.1023/A:1018782708070 Oral Glycoprotein IIb/IIIa Antagonists: New Insights from the SYMPHONY Trial [Elektronische Daten] [Darren McGuire, L. Newby] Platelet aggregation plays a central role in the pathophysiology of acute coronary syndromes, and the platelet glycoprotein IIb/IIIa receptor has been identified as the critical final mediator of this process. Antagonists of this receptor used parenterally during both acute coronary syndromes and percutaneous coronary interventions reduce the likelihood of subsequent major cardiac complications. However, after the treatment period little further benefit accrues. Based on these observations and that of the significant benefit of aspirin in cardiovascular secondary prevention, oral glycoprotein IIb/IIIa receptor antagonists are being evaluated with the goal of extending the benefit of glycoprotein IIb/IIIa inhibition into chronic secondary prevention. This paper will review the results of the SYMPHONY study of one such oral agent, sibrafiban, and the current state of the oral glycoprotein IIb/IIIa inhibitor field. Kluwer Academic Publishers, 2000 coronary artery disease nationallicence platelets nationallicence secondary prevention nationallicence platelet aggregation inhibitors nationallicence glycoprotein IIb/IIIa inhibitors nationallicence McGuire Darren Duke Clinical Research Institute, Durham, North Carolina, USA aut Newby L. Duke Clinical Research Institute, Durham, North Carolina, USA aut Journal of Thrombosis and Thrombolysis Kluwer Academic Publishers 10/2(2000-10-01), 111-119 0929-5305 10:2<111 2000 10 11239 https://doi.org/10.1023/A:1018782708070 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1023/A:1018782708070 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- McGuire Darren Duke Clinical Research Institute, Durham, North Carolina, USA aut NATIONALLICENCE 700 1- Newby L. Duke Clinical Research Institute, Durham, North Carolina, USA aut NATIONALLICENCE 773 0- Journal of Thrombosis and Thrombolysis Kluwer Academic Publishers 10/2(2000-10-01), 111-119 0929-5305 10:2<111 2000 10 11239 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer